Wednesday, January 18, 2012

Alliance Life Sciences Sponsors CBI Compliance Congress 2012 and Releases White Paper on Proposed Rules for Sunshine Act Implementation

Alliance Life Sciences Consulting Group (ALSCG), a leading management and technology consultancy, will be sponsoring the 2012 CBI Compliance Congress, January 24-25, 2012, Washington D.C. Coinciding with the event, Alliance is releasing a new White Paper on the proposed rules for Sunshine Act Implementation released by CMS on December 14, 2011.

The late release of the proposed rules has delayed the implementation of the act, as they will not be issued in their final form until at least mid-way through 2012. CMS is currently collecting comments until February 17, 2012. This means that companies did not have to comply with the original date of January 1, 2012 for starting to capture the data; however they will be required to submit a partial year once final rules are released. The White Paper further breaks down how the requirements differ from expected, and how to proactively approach compliance. It is available for download at:

"Life sciences companies spent much of 2011 implementing spend management programs with little direction from CMS," says Ed Masterson, senior vice president, consulting operations, ALSCG. "Now that the dates for reporting have changed, it allows a window for an intensive review to ensure compliance with both state and federal regulations."

Attendees at the CBI Compliance Congress are invited to visit the Alliance booth and speak with subject matter experts on the challenges posed by Aggregate Spend Reporting.


Formed in 1994 and headquartered in Somerset, N.J., Alliance Life Sciences Consulting Group employs more than 175 professionals who collectively understand the business challenges of the Life Sciences industry and offer solutions for Sales & Marketing, Managed Care & Government Contracting, Commercial Operations, Information Management and Analytics. ALSCG has experience with seven of the top 10 largest pharmaceutical manufacturers as well as middle market and emerging Life Sciences firms.

No comments: